Skip to main content
SpringerLink
Log in

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: An Illinois Cancer Council phase II study

  • Phase II Studies
  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Van Hoff DD, Myers JN, Kuhn J, Sandbach JF, Pocelinko R, Clark G, Coltman Jr CA: Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (CL 216,942). Cancer Res 41: 3118–3121, 1981

    Google Scholar 

  2. Murphy GR, Slack NH: Response criteria for the USA National Prostatic Cancer project. Prostate 1: 375–382, 1980

    Google Scholar 

  3. Powis G, Kovach JS: Deposition of bisantrene in humans and rabbits: evidence for intra-vascular deposition of drug as a cause of phlebitis. Cancer Res 43: 1402–1404, 1983

    Google Scholar 

  4. Marschke RF, Kvols LK, Cullinan SA, Laurie JA, Mailliard JA, Tschetter LK, O'Connell MJ: Phase II study of bisantrene administered by continuous 72-hour infusion for advanced pancreatic adenocarcinoma. Med Ped One 16: 269–270, 1988

    Google Scholar 

  5. Raghavan D, Bishop J, Woods R, Page J, Devine R: Mitozantrone (ZAN): A non-toxic moderately active agent for hormone-resistant prostate cancer. (Abstr) Proc Am Soc Clin Oncol 5: 102, #395, 1986

    Google Scholar 

  6. Drelichman A, Osborne CK, Von Hoff D: A phase II clinical investigation of dihydroxyanthracenedione (DHAD) in patients with advanced prostate cancer. (Abstr) Proc Am Soc Clin Oncol 1: 120, #465, 1982

    Google Scholar 

  7. Luz Hammershaimb, M.D., Lederle Laboratories: Personal communication, May 2, 1989

Download references

Author information

Authors and Affiliations

  1. University of Chicago Hospitals, Chicago, Illinois

    Nicholas J. Vogelzang

  2. Southern Illinois University School of Medicine, Springfield, Illinois

    Victor J. Lanzotti

  3. Illinois Cancer Council, Chicago, Illinois

    Betty Muntean & Richard R. Blough

Authors
  1. Nicholas J. Vogelzang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victor J. Lanzotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Betty Muntean
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard R. Blough
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogelzang, N.J., Lanzotti, V.J., Muntean, B. et al. Bisantrene in advanced, hormone-resistant carcinoma of the prostate: An Illinois Cancer Council phase II study. Invest New Drugs 8, 313–315 (1990). https://doi.org/10.1007/BF00171845

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00171845

Key words

Search

Navigation